Daniel Burge

5.1k total citations · 2 hit papers
23 papers, 3.9k citations indexed

About

Daniel Burge is a scholar working on Immunology, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Burge has authored 23 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Rheumatology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Burge's work include Psoriasis: Treatment and Pathogenesis (8 papers), Systemic Lupus Erythematosus Research (7 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Daniel Burge is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Systemic Lupus Erythematosus Research (7 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Daniel Burge collaborates with scholars based in United States, Germany and Belgium. Daniel Burge's co-authors include Joel M. Kremer, Ken J. Bulpitt, Michael E. Weinblatt, Barbara Finck, Roy Fleischmann, M. Lange, Arthur D. Bankhurst, Philip J. Mease, Ann VanderStoep and James M. Metz and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Daniel Burge

22 papers receiving 3.7k citations

Hit Papers

A Trial of Etanercept, a Recombinant Tumor Necrosis Facto... 1999 2026 2008 2017 1999 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
    1999 1.6k citations Michael E. Weinblatt, Joel M. Kremer et al. New England Journal of Medicine profile →
  2. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
    2000 1.1k citations Philip J. Mease, Bernard S. Goffe et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Burge United States 14 2.6k 1.6k 1.5k 357 355 23 3.9k
Barbara Finck United States 8 2.7k 1.0× 1.3k 0.8× 1.5k 1.0× 267 0.7× 184 0.5× 17 3.6k
Joseph Wajdula United States 21 2.7k 1.0× 1.1k 0.7× 1.2k 0.8× 254 0.7× 174 0.5× 35 3.4k
J. Wollenhaupt Germany 28 4.1k 1.5× 2.3k 1.4× 2.1k 1.4× 257 0.7× 327 0.9× 124 5.2k
Elizabeth C. Hsia United States 34 3.1k 1.2× 1.7k 1.0× 1.6k 1.1× 234 0.7× 254 0.7× 109 3.9k
Mittie K. Doyle United States 24 2.0k 0.7× 1.4k 0.9× 1.2k 0.8× 166 0.5× 367 1.0× 41 3.1k
Hideto Kameda Japan 38 2.6k 1.0× 1.2k 0.7× 1.2k 0.8× 266 0.7× 134 0.4× 196 4.3k
Hanno B. Richards United States 35 3.4k 1.3× 3.5k 2.1× 1.5k 1.0× 249 0.7× 411 1.2× 58 5.0k
John J. Cush United States 31 2.5k 1.0× 1.6k 1.0× 1.2k 0.8× 418 1.2× 100 0.3× 59 4.3k
Kimberly L. DeWoody United States 9 2.1k 0.8× 2.2k 1.3× 1.3k 0.8× 237 0.7× 94 0.3× 13 7.3k
Luminita Pricop United States 30 2.7k 1.0× 3.5k 2.2× 1.6k 1.1× 696 1.9× 531 1.5× 115 4.7k

Countries citing papers authored by Daniel Burge

Since Specialization
Citations

This map shows the geographic impact of Daniel Burge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Burge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Burge more than expected).

Fields of papers citing papers by Daniel Burge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Burge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Burge. The network helps show where Daniel Burge may publish in the future.

Co-authorship network of co-authors of Daniel Burge

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Burge. A scholar is included among the top collaborators of Daniel Burge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Burge. Daniel Burge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burge, Daniel, Victoria P. Werth, Susan A. Boackle, & James Posada. (2024). Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132. Lupus Science & Medicine. 11(1). e001113–e001113. 8 indexed citations
2.
Posada, James, Saba Valadkhan, Daniel Burge, et al.. (2020). Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial. Arthritis & Rheumatology. 73(1). 143–150. 46 indexed citations
3.
Fisher, Benjamin A., Francesca Barone, Peter Gallagher, et al.. (2019). OP0202 EFFECT OF RSLV-132 ON FATIGUE IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME – RESULTS OF A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY. Annals of the Rheumatic Diseases. 78. 177–177. 7 indexed citations
4.
Lebwohl, Mark, Andrew Blauvelt, C. Paul, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology. 79(2). 266–276.e5. 101 indexed citations
5.
Gottlieb, Alice B., Andrew Blauvelt, Diamant Thaçi, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology. 79(2). 302–314.e6. 121 indexed citations
6.
Blauvelt, Andrew, Kristian Reich, Mark Lebwohl, et al.. (2018). Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine. 2. S3–S3. 1 indexed citations
7.
Blauvelt, Andrew, Kristian Reich, Mark Lebwohl, et al.. (2018). Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. 33(3). 546–552. 30 indexed citations
8.
Piguet, Vincent, Andrew Blauvelt, Daniel Burge, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). SKIN The Journal of Cutaneous Medicine. 1. s3–s3. 1 indexed citations
9.
Thaçi, Diamant, Alice B. Gottlieb, Kristian Reich, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 1. s4–s4. 1 indexed citations
10.
11.
12.
Keystone, Edward, Michael Schiff, Joel M. Kremer, et al.. (2004). Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism. 50(2). 353–363. 227 indexed citations
13.
Mease, Phillip J., Christopher T. Ritchlin, Richard W. Martin, et al.. (2004). Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.. PubMed. 31(7). 1356–61. 110 indexed citations
14.
Wanke, Lee A., Philip Mease, Alice B. Gottlieb, & Daniel Burge. (2004). Sustained improvement in activities of daily living and vitality in patients with psoriatic arthritis treated with etanercept. Journal of the American Academy of Dermatology. 50(3). P145–P145. 4 indexed citations
15.
Lovell, Daniel J., Edward H. Giannini, Andreas Reiff, et al.. (2003). Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial. Arthritis & Rheumatism. 48(1). 218–226. 182 indexed citations
16.
Kremer, Joel M., Michael E. Weinblatt, Arthur D. Bankhurst, et al.. (2003). Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations. Arthritis & Rheumatism. 48(6). 1493–1499. 85 indexed citations
17.
Moreland, Larry W., S. Cohen, Scott W. Baumgartner, et al.. (2001). Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.. PubMed. 28(6). 1238–44. 154 indexed citations
18.
Mease, Philip J., Bernard S. Goffe, James M. Metz, et al.. (2000). Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. The Lancet. 356(9227). 385–390. 1111 indexed citations breakdown →
19.
Weinblatt, Michael E., Joel M. Kremer, Arthur D. Bankhurst, et al.. (1999). A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. New England Journal of Medicine. 340(4). 253–259. 1612 indexed citations breakdown →
20.
Burge, Daniel, et al.. (1961). Pheochromocytoma in a child.. PubMed. 50. 381–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Finck Breakdown of academic impact, for papers by Joseph Wajdula Breakdown of academic impact, for papers by J. Wollenhaupt Breakdown of academic impact, for papers by Elizabeth C. Hsia Breakdown of academic impact, for papers by Mittie K. Doyle Breakdown of academic impact, for papers by Hideto Kameda Breakdown of academic impact, for papers by Hanno B. Richards Breakdown of academic impact, for papers by John J. Cush Breakdown of academic impact, for papers by Kimberly L. DeWoody Breakdown of academic impact, for papers by Luminita Pricop
Rankless by CCL
2026